Enjoy complimentary customisation on priority with our Enterprise License!
The anorexiants market size is forecast to increase by USD 1.02 billion at a CAGR of 4.5% between 2023 and 2028. The market is witnessing significant growth due to the increasing prevalence of obesity, type 2 diabetes, and the approval of new therapeutics for weight loss. The market is segmented into three main categories: online pharmacy, retail pharmacy, and hospital pharmacy. The growing trend of online pharmacy sales is contributing to the market's expansion, as consumers seek convenience and affordability. Catecholamine anorexiants, such as phentermine and diethylpropion, remain popular choices for weight loss. However, the safety and tolerability profiles of these drugs limit their widespread use, particularly among vulnerable populations like children and adolescents, the geriatric population, and those with health and wellness concerns, such as type 2 diabetes. New drugs, such as those targeting neuropeptides and melanocortin receptors, are under development to address these concerns.
Additionally, there is a growing focus on the use of anorexiants for the treatment of specific conditions, such as Attention Deficit Hyperactivity Disorder (ADHD) and neurological disorders like Dravet Syndrome and Lennox Gastaut Syndrome. These indications offer significant growth opportunities for market players, as they expand the addressable patient population.
Anorexiants, also known as appetite suppressants, are pharmaceutical compounds used to reduce hunger and increase satiety. The prevalence of sedentary lifestyles, physical inactivity, and unhealthy dietary habits have led to a significant increase in the number of individuals suffering from obesity and related health conditions such as cardiovascular diseases, diabetes, and hypertension. According to the World Health Organization, over 1.9 billion adults were overweight or obese in 2016. Anorexiants play a crucial role in managing weight loss for individuals diagnosed with various conditions, including obesity, ADHD, Dravet syndrome, and Lennox-Gastaut syndrome.
In addition, these conditions can lead to excessive weight gain and complicate the management of underlying health issues. Anorexiants can be administered orally or subcutaneously in the form of tablets, capsules, or subcutaneous injections. The market for anorexiants is driven by several factors. The rising prevalence of obesity and obesity-related health conditions is a significant factor. Additionally, the increasing awareness of the health risks associated with obesity and the availability of various treatment options are expected to fuel market growth. Furthermore, the growing number of hospitals, specialty clinics, and homecare services offering weight loss programs is expected to create new opportunities for anorexiants.
Furthermore, catecholamines anorexiants and serotonin anorexiants are the two primary types of anorexiants. Catecholamines anorexiants, also known as sympathomimetic anorexiants, work by stimulating the sympathetic nervous system, which leads to an increase in heart rate, blood pressure, and metabolism. Serotonin anorexiants, on the other hand, work by increasing the levels of serotonin in the brain, which helps regulate appetite. The use of anorexiants is not without risks, and their long-term use can lead to various side effects, including cardiovascular problems, high blood pressure, and psychiatric disorders. Therefore, it is essential to monitor patients closely while using anorexiants and follow the prescribed dosage carefully.
In conclusion, the market is expected to grow significantly due to the increasing prevalence of obesity and related health conditions, growing awareness of weight management, and the availability of various treatment options. The market is segmented into catecholamines anorexiants and serotonin anorexiants, with each segment offering unique benefits and challenges. It is crucial to ensure proper patient monitoring and adherence to prescribed dosages to minimize potential risks.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. In the pharmaceutical industry, hospital pharmacies play a crucial role in dispensing medications developed by pharmaceutical companies. These companies conduct extensive research and development (R&D) to create and perfect drugs, which are then submitted to the US Food and Drug Administration (FDA) for approval. The FDA evaluates various aspects of the drug, including its dosage form, chemistry, safety, efficacy, manufacturing methodology, labeling, and packaging, before granting approval. The prevalence of chronic conditions like morbid obesity and an increase in childhood obesity, coupled with the growing consumer demand for obesity treatments, is expected to boost the demand for obesity drugs.
Moreover, this trend will positively impact the hospital pharmacy segment. However, the increasing penetration of online pharmacies in both developing and developed countries may negatively influence the growth of this segment. Anorexiants, a type of therapeutics, are used for weight loss treatment. These medications work by increasing the levels of catecholamines in the body, which help suppress appetite.
Get a glance at the market share of various segments Request Free Sample
The hospital pharmacy segment accounted for USD 2.14 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 52% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America, specifically in the United States, held a significant market share in 2023 and is projected to maintain its dominance throughout the forecast period. In 2020, the US generated the highest revenue from the sales of four FDA-approved anti-obesity drugs: Lorcaserin, Naltrexone, Orlistat, and Liraglutide. Mexico and Canada also have high obesity rates, with Mexico reporting an increase of nearly 4 percentage points in the percentage of adults aged 20 and above who were either overweight or obese between 2015 and 2021, according to US News. In 2020, the obesity rate in Saskatchewan, Canada, was approximately 45%.
In addition, these chronic diseases are linked to the hypothalamus and limbic parts of the brain, which control satiety and appetite. Anti-obesity drugs, such as LorcaserinER, Phentermine, and Orlistat, are used in conjunction with a low-calorie diet and regular exercise to manage weight. Breast cancer survivors are also at a higher risk of obesity and may benefit from these medications. The market is expected to grow due to the increasing prevalence of obesity and associated health issues.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing obese population is the key driver of the market. Obesity is a significant health concern worldwide, with chronic conditions such as colon cancer, endometrial cancer, type 2 diabetes, and cardiovascular disease being associated with this condition. The prevalence of obesity is high due to factors like family lifestyle, genetics, and bad nutrition. In the US, obesity has been a major issue for over two decades. The rise in sedentary lifestyles and inactivity have contributed to this trend. The healthcare expenditure for managing obesity-related health issues is substantial. Consumers are now prioritizing their health and seeking effective solutions. The pharmaceutical industry has been developing branded drugs to address obesity, with a focus on targeting the underlying causes.
However, the limited efficacy of current treatments has left room for innovation. Obesity's impact on musculoskeletal issues is another concern. The increased demand for effective obesity treatments is driving the market growth. As per market research, the obesity market is expected to witness steady growth in the coming years. This trend is expected to continue as consumers become more health-conscious and seek effective solutions to manage their weight and related health issues.
Research and approval of new drugs is the upcoming trend in the market. Anorexiants, a type of weight loss medications, have gained significant attention due to the increasing prevalence of obesity and associated health issues such as cardiovascular diseases, diabetes, and hypertension. Sedentary lifestyles, physical inactivity, and unhealthy dietary habits are major contributors to obesity. According to the World Health Organization, obesity has more than doubled worldwide since 1980. Pharmaceutical companies are investing heavily in the research and development of new anorexiant drugs to address this global health concern. For instance, in June 2021, the US Food and Drug Administration (FDA) approved semaglutide, an injectable medication for weight management among overweight or obese adults.
In addition, this drug works by reducing hunger and increasing feelings of fullness, thereby helping individuals consume fewer calories. The FDA's approval of Wegovy, a semaglutide-based anorexiant, was based on the positive results from four phase III clinical trials involving over 4,500 participants. These trials confirmed the drug's safety and efficacy in managing weight. The approval of Wegovy marks a significant milestone in the fight against obesity and its related health complications. This trend is expected to continue as more innovative anorexiant drugs enter the market, providing relief to millions of people struggling with weight management.
Low safety and tolerability profile of anti-obesity drugs is a key challenge affecting the market growth. The use of anorexiants, or anti-obesity drugs, has become a topic of interest due to the increasing prevalence of obesity and related health issues. These medications work by suppressing appetite, increasing metabolism, or preventing fat absorption. However, they come with potential risks and side effects that may outweigh their benefits. Anorexiants can cause diarrhea, headache, nausea, vomiting, and dry mouth. More severe side effects include insomnia, increased heart rate, tremors, and blurred vision. These drugs are not recommended for everyone, and their use is limited to a select group of adults due to safety concerns. It is essential to be aware of these side effects and consult a healthcare professional before using anorexiants to manage weight.
Furthermore, adherence rates to these medications can be low due to their side effects and potential risks. According to epidemiological studies, the prevalence of obesity and related conditions continues to rise, making the need for effective weight management options more pressing. It is crucial to weigh the benefits against the risks before considering anorexiants as a solution.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Epic Pharma LLC - The company offers anorexiants that is an appetite suppressant that affects the central nervous system.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Anorexiants, also known as weight loss medications, are pharmaceutical compounds designed to reduce appetite and help individuals manage their weight. The global market for anorexiants is driven by the prevalence of sedentary lifestyles, physical inactivity, and unhealthy dietary habits leading to obesity and related health conditions such as cardiovascular diseases, diabetes, and hypertension. According to the World Health Organization, obesity has reached epidemic proportions globally, affecting over 650 million people. Two main types of anorexiants exist: catecholamines and serotonin anorexiants. The former work by stimulating the central nervous system (CNS), while the latter affect the brain's limbic parts and hypothalamus, which control satiety.
Moreover, anorexiants are available in various forms, including tablets and capsules, and are administered through retail pharmacies, online pharmacies, hospitals, specialty clinics, and homecare settings. Anorexiants are used to treat various conditions, including obesity, ADHD, Dravet syndrome, Lennox-Gastaut syndrome, and binge eating disorder. They are also used in the therapeutic management of chronic diseases like breast, colon cancer, type 2 diabetes, endometrial cancer, and cardiovascular disease. Skilled professionals often prescribe anorexiants to children and adolescents, geriatric populations, and those with a Body Mass Index (BMI) above the healthy range. Despite their benefits, anorexiants come with potential side effects, including diarrhea, tachycardia, headache, myalgia, insomnia, nausea, and vomiting. Long-term use can lead to mortality and decreased adherence rates. Anorexiants are subject to healthcare expenditure and drug development, with branded drugs often carrying higher prices than generic alternatives. It is essential to consult with healthcare professionals before using anorexiants to manage weight and related health conditions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
138 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
|
Market growth 2024-2028 |
USD 1.02 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.23 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 52% |
|
Key countries |
US, Canada, UK, Germany, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Bausch Health Companies Inc., Currax Pharmaceuticals LLC, Elite Pharmaceuticals Inc., Epic Pharma LLC, F. Hoffmann La Roche Ltd., Hi Tech Pharmaceuticals, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc., KVK Tech Inc., Lannett Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Recordati S.p.A, Searchlight Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Virtus Nutrition LLC, VIVUS LLC, and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
